Artificial Intelligence–Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population

Anthony H. Kashou, Jose R. Medina-Inojosa, Peter A. Noseworthy, Richard J. Rodeheffer, Francisco Lopez-Jimenez, Itzhak Zachi Attia, Suraj Kapa, Christopher G. Scott, Alexander T. Lee, Paul A. Friedman, Paul M. McKie

Research output: Contribution to journalArticlepeer-review


Objective: To validate an artificial intelligence–augmented electrocardiogram (AI-ECG) algorithm for the detection of preclinical left ventricular systolic dysfunction (LVSD) in a large community-based cohort. Methods: We identified a randomly selected community-based cohort of 2041 subjects age 45 years or older in Olmsted County, Minnesota. All participants underwent a study echocardiogram and ECG. We first assessed the performance of the AI-ECG to identify LVSD (ejection fraction ≤40%). After excluding participants with clinical heart failure, we further assessed the AI-ECG to detect preclinical LVSD among all patients (n=1996) and in a high-risk subgroup (n=1348). Next we modelled an imputed screening program for preclinical LVSD detection where a positive AI-ECG triggered an echocardiogram. Finally, we assessed the ability of the AI-ECG to predict future LVSD. Participants were enrolled between January 1, 1997, and September 30, 2000; and LVSD surveillance was performed for 10 years after enrollment. Results: For detection of LVSD in the total population (prevalence, 2.0%), the area under the receiver operating curve for AI-ECG was 0.97 (sensitivity, 90%; specificity, 92%); in the high-risk subgroup (prevalence 2.7%), the area under the curve was 0.97 (sensitivity, 92%; specificity, 93%). In an imputed screening program, identification of one preclinical LSVD case would require 88.3 AI-ECGs and 8.7 echocardiograms in the total population and 65.7 AI-ECGs and 5.5 echocardiograms in the high-risk subgroup. The unadjusted hazard ratio for a positive AI-ECG for incident LVSD over 10 years was 2.31 (95% CI, 1.32 to 4.05; P=.004). Conclusion: Artificial intelligence–augmented ECG can identify preclinical LVSD in the community and warrants further study as a screening tool for preclinical LVSD.

Original languageEnglish (US)
Pages (from-to)2576-2586
Number of pages11
JournalMayo Clinic proceedings
Issue number10
StatePublished - Oct 2021

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Artificial Intelligence–Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population'. Together they form a unique fingerprint.

Cite this